









Markets
/
Stocks
/
nasdaq-roiv
/

Roivant Sciences Ltd

ROIV

27.360USD

+0.490+1.82%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

18.74BMarket Cap

LossP/E TTM



Roivant Sciences Ltd

27.360

+0.490+1.82%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Roivant Sciences Ltd

Currency: USD Updated: 2026-03-25

Key Insights

Roivant Sciences Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 46 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.45.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Roivant Sciences Ltd's Score

Industry at a Glance

Industry Ranking

46 / 157

Overall Ranking

137 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Roivant Sciences Ltd Highlights

StrengthsRisks

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.05M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -23.53, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 545.59M shares, decreasing 4.55% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.38K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.15.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

32.455

Target Price

+16.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Roivant Sciences Ltd is 6.26, ranking 142 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.00M, representing a year-over-year decrease of 77.83%, while its net profit experienced a year-over-year decrease of 256.98%.

Score

Industry at a Glance

Previous score

6.26

Change



Financials

9.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Roivant Sciences Ltd's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Roivant Sciences Ltd is 7.28, ranking 82 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -23.53, which is -108.99% below the recent high of 2.11 and -164.98% above the recent low of -62.35.

Score

Industry at a Glance

Previous score

7.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Roivant Sciences Ltd is 8.77, ranking 7 out of 157 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 29.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.77

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

32.455

Target Price

+16.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Roivant Sciences Ltd

ROIV

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Roivant Sciences Ltd is 6.89, ranking 70 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 29.60 and the support level at 25.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.741

Neutral

RSI(14)

48.288

Neutral

STOCH(KDJ)(9,3,3)

22.483

Neutral

ATR(14)

1.025

Low Volatility

CCI(14)

-90.677

Neutral

Williams %R

79.412

Sell

TRIX(12,20)

0.186

Sell

StochRSI(14)

48.949

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

27.532

Sell

MA10

27.865

Sell

MA20

28.443

Sell

MA50

26.126

Buy

MA100

23.634

Buy

MA200

18.422

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Roivant Sciences Ltd is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 76.23%, representing a quarter-over-quarter decrease of 1.17%. The largest institutional shareholder is The Vanguard, holding a total of 41.97M shares, representing 5.86% of shares outstanding, with 2.02% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dexcel Pharma Technologies, Ltd.

102.85M

Fidelity Management & Research Company LLC

60.73M

+9.44%

Morgan Stanley Investment Management Inc. (US)

40.65M

+21.82%

The Vanguard Group, Inc.

Star Investors

38.72M

-1.33%

BlackRock Institutional Trust Company, N.A.

35.76M

+0.66%

Ramaswamy (Vivek)

47.07M

-0.00%

QVT Financial LP

28.08M

-4.42%

State Street Investment Management (US)

18.70M

-5.43%

SB Investment Advisers (UK) Limited

40.32M

-32.76%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Roivant Sciences Ltd is 8.62, ranking 23 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Roivant Sciences Ltd’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.